We canβt show the full text here under this license. Use the link below to read it at the source.
Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study
Timed Temozolomide Treatment in Glioblastoma Patients: A Retrospective Study
AI simplified
Abstract
Patients taking morning temozolomide experienced a longer median overall survival of 1.43 years compared to 1.13 years for those taking it in the evening.
- Morning administration of temozolomide is associated with improved overall survival in glioblastoma patients.
- The difference in median overall survival suggests a potential benefit of timing in treatment delivery.
- Among patients with MGMT-methylated tumors, morning treatment resulted in a median overall survival increase of 6 months.
- Significant survival differences favoring morning administration were observed at years 1, 2, and 5.
- Preliminary findings indicate that chronotherapy may enhance treatment outcomes for glioblastoma patients, particularly those with specific genetic markers.
AI simplified
Key numbers
1.43 years
Median (AM vs. PM)
Median for patients receiving morning .
6 months
Improvement in MGMT-methylated Patients
Difference in median for MGMT-methylated patients.
180
Total Patients Analyzed
Total number of glioblastoma patients included in the study.